FDA clears CathEffects' mapping system:
This article was originally published in Clinica
CathEffects has received US clearance to market its cardiac electrophysiology mapping system for use with its previously FDA-cleared five-electrode two-plane mapping catheter (see Clinica No 978, p 17). The Desai VectorCath mapping system offers an economic product that reduces mapping time and improves accuracy," said Shawn Fojtik, the firm's COO. "The mapping system is inexpensive when compared to other systems, requires almost no procedure set-up time, and delivers instantaneous mapping data," Mr Fojtik added.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.